## BDX: Becton, Dickinson and Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.4% below STRENGTH zone (3.0-6.0%); PEG 1.01 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($188.56)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. RBC Sees Durable Growth Profile at Becton Dickinson (BDX), Raises Target**
- Source: Insider Monkey | 20260102T182100 | Neutral | Relevance: 100%
- RBC Capital has raised its price target for Becton, Dickinson and Company (BDX) to $210, maintaining a Sector Perform rating, citing the company's durable growth profile supported by aging demographics and recurring revenue. However, BDX faces a lawsuit from a rival medical device maker, Tela Bio, alleging anti-competitive behavior in the surgical hernia mesh market. Despite the lawsuit and a 13% decline in stock price since early 2025, RBC remains constructive on BDX's mid-single-digit growth potential.

**2. Becton, Dickinson and Company $BDX Shares Sold by Lazard Freres Gestion S.A.S.**
- Source: MarketBeat | 20260102T121129 | Neutral | Relevance: 100%
- Lazard Freres Gestion S.A.S. reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 10.2% in Q3, selling 52,323 shares and now holding 461,790 shares valued at approximately $86.43 million. Despite this, several other large institutional investors, including Vanguard Group Inc., First Eagle Investment Management LLC, and Massachusetts Financial Services Co. MA, significantly increased their holdings in BDX during the same period, with Norges Bank acquiring a new stake worth about $653 million. The company recently increased its quarterly dividend to $1.05 per share, and analysts currently have a consensus "Hold" rating with an average price target of $205.64.

**3. The Truth About Becton Dickinson & Co (BDX): Quiet Giant Or Sleeper Stock You’re Sleeping On?**
- Source: AD HOC NEWS | 20260102T000748 | Bullish | Relevance: 100%
- This article examines Becton Dickinson & Co (BDX), a healthcare giant behind essential medical supplies, arguing it's a solid long-term investment despite lacking "meme stock" appeal. It highlights BDX's stable business model rooted in consistent demand for indispensable hospital equipment and its steady compounding growth. The piece concludes that BDX is a "COP" for serious, diversified portfolios due to its foundational role in healthcare.

**4. The Truth About Becton Dickinson & Co (BDX): Quiet Giant Or Sleeper Stock You’re Sleeping On?**
- Source: AD HOC NEWS | 20260102T000147 | Bullish | Relevance: 100%
- Becton Dickinson & Co (BDX) is a healthcare giant that, while not considered "flashy" or a "meme stock," plays a crucial role in modern healthcare by providing essential medical equipment. This article examines why BDX, despite its low profile, is a preferred stock for serious investors due to its stable business model, consistent demand, and steady growth. It compares BDX to competitors like Baxter International and concludes that it is a solid long-term investment for a diversified portfolio.

**5. Who Owns Becton, Dickinson and Company? Top Shareholders and Recent Insider Trades**
- Source: TIKR.com | 20260101T130755 | Neutral | Relevance: 100%
- This article examines Becton, Dickinson and Company's (NYSE: BDX) ownership structure, highlighting the dominance of large institutional investors and recent insider trading activities. While institutional support provides stability, insider behavior appears neutral, suggesting that BDX remains a stable healthcare holding rather than a high-conviction trade. The analysis also covers significant changes in holdings by various asset managers and hedge funds.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | RBC Capital | $210 | $202 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | RBC Capital | main | Sector Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 13 ($0.04M) |
| Sells | 5 ($0.06M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 10 / 0 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (+0.5%)
- Blackrock Inc.: 9.7% (+1.7%)
- T. Rowe Price Invest: 5.7% (+0.3%)
- State Street Corpora: 4.9% (+3.4%)
- JPMORGAN CHASE & CO: 3.7% (+132.7%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +2.0% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.01 suggests fair value with growth premium. Balance sheet: $2.7B free cash flow. Institutional flow bullish (10 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $55.6B |
| Beta | 0.28 |
| 52W Range | $162.29 - $251.99 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.01 |
| Forward P/E | 12.3 |
| Current P/E | 13.0 |
| YoY Growth | 6.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.7% to 0.4% (+2.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.6pp (needs >3.0% for momentum thesis). MRS_5 at 0.5% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.03x) but short-term weakness (below SMA20). MACD histogram bearish (-0.51), momentum weakening. RSI neutral at 52. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.37% (CS: 43) | Neutral |
| RSI_14 | 51.7 | Neutral |
| MACD Histogram | -0.51 | Bearish |
| vs SMA20 | 0.996x | Below |
| vs SMA50 | 1.023x | Above |
| vs SMA200 | 1.034x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $194.94
- **Stop Loss:** $188.56 (3.3% risk)
- **Target:** $201.32 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 225
- **Position Value:** $43,861.50
- **Portfolio %:** 43.86%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-09 (Est: $2.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.91 | $3.96 | +1.1% |
| 2025Q2 | $3.40 | $3.68 | +8.2% |
| 2025Q1 | $3.28 | $3.35 | +2.1% |
| 2024Q4 | $2.99 | $3.43 | +14.7% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*